Key Facts
- CAS
- —
- Molecular Weight (MW)
- ≈5000 g/mol
- Half-life
- Short; stabilized vs native relaxin-2
- Unit
- mcg
- Administration Route
- —
- Frequency
- —
- Last updated
- 2/17/2026
- Targets
- RXFP1
Overview
—
Protocol
- Dosage Range
- Per research protocol
- Frequency
- —
- Cycle
- —
- Administration Route
- —
- Reconstitution Guide
- —
Science
Mechanism of Action
RXFP1 agonist, activates ERK1/2, upregulates MMPs, anti-fibrotic.
Targets
RXFP1
Studies
- — Journal/year not available
Benefits
Reduces fibrosisCardioprotectionVasodilation
Potential Side Effects
- Not fully established
References
References coming soon.
Suggest a reference